Treating patients with COVID-19 in critical condition with corticosteroids reduces the death threat by 20%, a foreign investigation from seven trials discovered Wednesday, which led the World Health Organization to update its recommendations on remedies.
Research, which included knowledge of separate trials on hydrocortisone, dexamethasone and low-dose methylprednisolone, found that steroids increased survival rates for COVID-19 patients who were sufficient to receive intensive care in the hospital.
“This equates to approximately 68% of patients (the sickest of COVID-19) surviving after corticosteroid treatment, and approximately 60% survive in the absence of corticosteroids,” the researchers said in a statement.
“Steroids are a reasonable and easy-to-get drug, and our research has shown that they are effective at reducing deaths among people most affected by COVID-19,” said Jonathan Sterne, professor of medical statistics and epidemiology at the University of the UK.Bristol, who worked on the investigation, said the report.
He said the trials, conducted through researchers in Britain, Brazil, Canada, China, France, Spain and the United States, gave a constant message at all times, apparently that the drugs were in patients who were sicker, regardless of age or gender or duration of patients.had been ill.
The findings, published in the Journal of the American Medical Association, were hailed as a breakthrough and announced in June, when dexamethasone became the first drug capable of reducing mortality rates in patients with COVID-19 in critical condition.
Since then, dexamethasone has been widely used in extensive care sets for the treatment of COVID-19 patients in some countries.
Martin Landray, professor of medicine and epidemiology at The University of Oxford who worked on the dexamethasone trial which is a key component of the grouped research published Wednesday, said the findings mean that doctors in hospitals around the world can safely switch to drug use.Lives.
CLEAR BENEFITS
“These effects are transparent and usable in clinical practice,” he told reporters.”Among patients critically ill with COVID-19, Low-Dose Array Corticosteroids …significantly reduce the threat of death.”
Researchers said the benefits of obtaining were demonstrated regardless of the fact that patients were ventilated at the time they started treatment, and said WHO would promptly update their rules to reflect the new findings.
Until the June findings of dexamethasone, no effective remedy had been demonstrated to reduce mortality rates in patients with COVID-19, the respiratory disease caused by the new coronavirus.
More than 25 million other people have become inflamed with COVID-19 and 856,876 have died, according to a Reuters count.
Gilead Sciences Inc.’s new employment approved through U.S. regulators is not a good factor in the united states that have been approved by U.S. regulators.But it’s not the first time In May for use in patients with severe COVID-19 after the trial knowledge showed that the antiviral drug had helped shorten recovery time in the hospital.
Anthony Gordon, a professor at Imperial College London who also worked on the analysis, said his findings were good news for patients who become seriously ill with COVID-19, but would not be enough to end epidemics or facilitate infection measures.
“As impressive as those effects may be, it’s not a cure.Now we have anything that can help, but it’s not a cure, so it’s important that we all have prevention strategies.”
(This article was published from a firm thread without converting the text, only the name has been changed).
Follow more on Facebook and Twitter
“item.title”